+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatology Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Dermatology Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Dermatology Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 5967940
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dermatology Drugs Market grew from USD 34.23 billion in 2024 to USD 37.71 billion in 2025. It is expected to continue growing at a CAGR of 9.99%, reaching USD 60.62 billion by 2030.

The global dermatology drug sector is witnessing unprecedented evolution driven by scientific breakthroughs, shifting patient expectations, and regulatory recalibrations. In recent years, targeted biologic therapies have redefined treatment paradigms, offering precision interventions that mitigate systemic side effects while delivering robust efficacy. Concurrently, rapid advances in formulation science are enhancing topical and systemic delivery, fostering improved adherence and clinical outcomes. This introduction sets the stage for a comprehensive exploration of how transformative shifts, policy developments, and nuanced market segmentation collectively shape the future of dermatology therapeutics. By examining the interplay of innovation, trade dynamics, and strategic positioning, stakeholders can navigate complexity with informed confidence.

As we progress, each subsequent section will unpack a critical dimension of this market-from tariff impacts on supply chains to granular insights into drug types, administration routes, clinical applications, and end-user segments. Through clear analysis and actionable guidance, this executive summary equips decision-makers with the knowledge required to capitalize on emerging opportunities, mitigate risks, and drive sustainable growth across the dermatology drug landscape.

Transformative Shifts Reshaping the Dermatology Drug Landscape

Over the past decade, the dermatology drug landscape has undergone transformative shifts that extend far beyond incremental innovation. The advent of monoclonal antibodies and fusion proteins has propelled targeted therapies into mainstream practice, displacing traditional small molecules in chronic inflammatory conditions and genetic skin disorders. Parallel advances in drug delivery have introduced subcutaneous and pre-filled injectable options, elevating patient convenience and adherence.

Digital health integration has further reshaped clinician-patient interactions, enabling remote monitoring of treatment response through mobile applications and teledermatology platforms. These technological enhancements not only streamline clinical workflows but also generate real-world evidence that informs product lifecycle strategies. Meanwhile, evolving regulatory frameworks have introduced expedited pathways for breakthrough therapies, compressing approval timelines without compromising safety standards.

This confluence of scientific, technological, and policy-related transformations demands dynamic strategic responses. Companies that embrace cross-functional collaboration-melding R&D, digital innovation, and regulatory expertise-are best positioned to harness these shifts. As a result, the competitive environment is advancing toward a model that prizes agility, patient centricity, and data-driven decision-making.

Assessing the 2025 Impact of U.S. Tariffs on Dermatology Drugs

In 2025, revised United States tariffs on imported dermatology drugs introduced a new layer of complexity to global supply chains and pricing strategies. Producers heavily reliant on active pharmaceutical ingredients sourced from international partners faced heightened input costs, prompting a reevaluation of sourcing logistics. Manufacturers that previously benefitted from low-cost raw material imports began to explore domestic contract manufacturing options and vertical integration models to stabilize margins.

Pharmaceutical companies also adjusted their pricing structures in response to these tariff pressures. In certain instances, list prices were recalibrated to offset incremental duties, affecting formulary negotiations and payer reimbursement agreements. Health systems undertook more rigorous value assessments, demanding robust pharmacoeconomic data to justify cost increases.

Despite these challenges, tariff-driven cost inflation catalyzed innovation in supply chain resilience. Firms accelerated the adoption of predictive analytics to anticipate customs delays and optimize inventory buffers. Ultimately, the 2025 tariff landscape underscored the imperative for diversified sourcing and agile procurement strategies, ensuring continuity of supply and competitive positioning amid evolving trade policies.

Key Insights from Market Segmentation Analysis

Detailed segmentation reveals how distinct market subsets respond to innovation and policy nuances. Segmenting by drug type highlights the growing prominence of biologic drugs, where fusion proteins and monoclonal antibodies command a significant share of R&D investment and clinical focus. Route of administration segmentation underscores the balance between injectable therapies-both intravenous and subcutaneous-and established oral and topical modalities, each catering to specific patient preferences and compliance profiles.

Application-based segmentation demonstrates that psoriasis remains a cornerstone indication, with clinical research differentiating guttate psoriasis from plaque psoriasis to tailor therapeutic regimens. End-user segmentation shows that dermatology clinics, encompassing group clinics and private clinics, operate alongside hospitals, reflecting varied patient access pathways and treatment settings.

Patient demographics segmentation categorizes populations by age group-adult patients split into young adults and middle-aged cohorts, alongside geriatric and pediatric groups-facilitating targeted dosing and formulation strategies. Formulation type segmentation encompasses liquid dosage forms, including solutions and suspensions, semi-solid preparations, and solid dosage forms such as capsules and tablets, each optimized for stability and administration convenience.

Therapeutic class segmentation spans antibiotics, further divided into oral antibiotics and topical antibiotics, corticosteroids, and retinoids, reflecting established standards of care. Lastly, drug delivery device segmentation highlights auto-injectors-disposable and reusable options-and pre-filled syringes, illustrating the emphasis on patient-friendly delivery systems that enhance adherence and reduce administration errors.

Critical Regional Perspectives in the Dermatology Drug Sector

Regional dynamics exhibit distinct drivers and market characteristics. In the Americas, robust healthcare infrastructure and high per capita expenditure sustain leadership in dermatology drug adoption, with innovative reimbursement models supporting early access. The Europe, Middle East & Africa region benefits from regulatory harmonization under frameworks such as the European Medicines Agency, fostering cross-border collaboration and streamlining launch sequences, while local manufacturing hubs in select markets improve supply reliability.

The Asia-Pacific region is marked by rapid growth fueled by expanding healthcare budgets, increasing incidence of skin disorders, and rising patient awareness. Emerging markets in this zone are attracting investment in both research collaborations and manufacturing facilities, as multinational and domestic players seek to capitalize on favorable demographics and evolving insurance coverage schemes.

Across all regions, digital health initiatives-ranging from teledermatology platforms to remote patient monitoring-are converging with traditional care pathways, reshaping the competitive landscape and enabling more patient-centric service models. Understanding these regional nuances is critical for companies to prioritize markets effectively, allocate resources, and adapt market access strategies.

Strategic Company Dynamics and Competitive Insights

Competitive dynamics are defined by a cohort of leading and emerging players, each leveraging distinct capabilities. Allergan plc by Abbvie Inc. and Almirall S.A. are advancing biologic portfolios, while Amgen Inc. and Arcutis Biotherapeutics, Inc. pioneer novel immunomodulatory therapies. Asterisk Laboratories and AstraZeneca plc are reinforcing their positions through diversified topical and systemic franchises. Bayer AG alongside Bristol-Myers Squibb Company are investing in combination therapies that address complex dermatological conditions.

Cipla Limited is expanding generic accessibility, and Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited alongside DermBiont, Inc. are focusing on targeted molecular treatments. Dr. Reddy's Laboratories and Eli Lilly and Company continue to broaden geographic reach through strategic partnerships. Meanwhile, F. Hoffmann-La Roche AG and Galderma S.A. are strengthening specialized formulations, and GlaxoSmithkline plc with Johnson & Johnson Services, Inc. leverage extensive pipelines to maintain market momentum.

Leo Pharma A/S and Lupin Ltd address demographic-specific therapeutic needs, whereas Mayne Pharma Group Ltd and Merck & Co., Inc. innovate in drug delivery technologies. Global titans Novartis AG and Pfizer Inc. explore advanced modalities such as gene-based interventions, while Roivant Sciences Ltd. and Shinom Cosmeceuticals integrate research-driven innovations with consumer-focused offerings. This competitive tableau underscores the imperative for differentiation through scientific excellence and responsive commercialization strategies.

Actionable Recommendations for Industry Leadership

Industry leaders should prioritize cross-functional innovation models that integrate R&D, commercial, and digital teams from early development stages to commercialization. Establishing agile partnerships with contract manufacturers and ingredient suppliers mitigates risks introduced by fluctuating trade policies. Companies can also deepen engagement with payers by generating robust real-world evidence through digital platforms, strengthening pharmacoeconomic value propositions.

To enhance market penetration, organizations should tailor formulations and delivery systems to specific patient subsegments identified through demographic and application-based analyses. Collaborative pilot programs with key dermatology clinics and hospital networks can validate new treatment paradigms and expedite adoption. Furthermore, investment in predictive supply chain analytics will bolster resilience against policy shifts and logistical constraints.

Finally, a proactive regulatory strategy that leverages accelerated approval pathways and harmonized submissions across regions will reduce time to market. By aligning clinical development plans with evolving patient needs and payer expectations, industry leaders can secure both clinical and commercial success.

Conclusion and Future Outlook

The dermatology drug market stands at the nexus of innovation, policy, and patient-centric care. As biologic therapies and advanced delivery technologies continue to redefine treatment standards, companies that combine scientific rigor with strategic agility will outpace competition. Navigating tariff-related challenges requires supply chain diversification and strong payer collaborations, while segmentation-driven product design ensures therapies meet the nuanced needs of distinct patient groups.

Looking ahead, the convergence of digital health solutions, real-world evidence, and regional market insights will chart the course for next-generation dermatology therapeutics. Organizations that harness these forces-guided by data, collaboration, and a relentless focus on patient outcomes-will shape the market’s future and achieve sustained growth.

Market Segmentation & Coverage

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologic Drugs
    • Fusion Proteins
    • Monoclonal Antibodies
  • Injectable
    • Intravenous
    • Subcutaneous
  • Oral
  • Topical
  • Psoriasis
    • Guttate Psoriasis
    • Plaque Psoriasis
  • Dermatology Clinics
    • Group Clinics
    • Private Clinics
  • Hospitals
  • Age Group
    • Adult
      • Middle Age
      • Young Adult
    • Geriatric
    • Pediatric
  • Liquid Dosage Forms
    • Solutions
    • Suspensions
  • Semi-Solid Forms
  • Solid Dosage Forms
    • Capsules
    • Tablets
  • Antibiotics
    • Oral Antibiotics
    • Topical Antibiotics
  • Corticosteroids
  • Retinoids
  • Auto-Injectors
    • Disposable
    • Reusable
  • Pre-Filled Syringes

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dermatology Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Allergan plc by Abbvie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • Asterisk Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • DermBiont, Inc.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma S.A.
  • GlaxoSmithkline plc
  • Johnson & Johnson Services, Inc.
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma Group Ltd
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Roivant Sciences Ltd.
  • Shinom Cosmeceuticals

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dermatology Drugs Market, by Drug Type
8.1. Introduction
8.2. Biologic Drugs
8.2.1. Fusion Proteins
8.2.2. Monoclonal Antibodies
9. Dermatology Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
9.4. Topical
10. Dermatology Drugs Market, by Application
10.1. Introduction
10.2. Psoriasis
10.2.1. Guttate Psoriasis
10.2.2. Plaque Psoriasis
11. Dermatology Drugs Market, by End Users
11.1. Introduction
11.2. Dermatology Clinics
11.2.1. Group Clinics
11.2.2. Private Clinics
11.3. Hospitals
12. Dermatology Drugs Market, by Patient Demographics
12.1. Introduction
12.2. Age Group
12.2.1. Adult
12.2.1.1. Middle Age
12.2.1.2. Young Adult
12.2.2. Geriatric
12.2.3. Pediatric
13. Dermatology Drugs Market, by Formulation Type
13.1. Introduction
13.2. Liquid Dosage Forms
13.2.1. Solutions
13.2.2. Suspensions
13.3. Semi-Solid Forms
13.4. Solid Dosage Forms
13.4.1. Capsules
13.4.2. Tablets
14. Dermatology Drugs Market, by Therapeutic Class
14.1. Introduction
14.2. Antibiotics
14.2.1. Oral Antibiotics
14.2.2. Topical Antibiotics
14.3. Corticosteroids
14.4. Retinoids
15. Dermatology Drugs Market, by Drug Delivery Devices
15.1. Introduction
15.2. Auto-Injectors
15.2.1. Disposable
15.2.2. Reusable
15.3. Pre-Filled Syringes
16. Americas Dermatology Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Dermatology Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Dermatology Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Allergan plc by Abbvie Inc.
19.3.2. Almirall S.A.
19.3.3. Amgen Inc.
19.3.4. Arcutis Biotherapeutics, Inc.
19.3.5. Asterisk Laboratories
19.3.6. AstraZeneca plc
19.3.7. Bayer AG
19.3.8. Bristol-Myers Squibb Company
19.3.9. Cipla Limited
19.3.10. Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
19.3.11. DermBiont, Inc.
19.3.12. Dr. Reddy's Laboratories
19.3.13. Eli Lilly and Company
19.3.14. F. Hoffmann-La Roche AG
19.3.15. Galderma S.A.
19.3.16. GlaxoSmithkline plc
19.3.17. Johnson & Johnson Services, Inc.
19.3.18. Leo Pharma A/S
19.3.19. Lupin Ltd
19.3.20. Mayne Pharma Group Ltd
19.3.21. Merck & Co., Inc
19.3.22. Novartis AG
19.3.23. Pfizer Inc.
19.3.24. Roivant Sciences Ltd.
19.3.25. Shinom Cosmeceuticals
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DERMATOLOGY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DERMATOLOGY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DERMATOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DERMATOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY GROUP CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY MIDDLE AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SEMI-SOLID FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 116. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 118. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 120. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 122. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 123. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 124. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 125. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 127. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 128. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 129. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 130. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 132. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 133. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 145. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 208. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 209. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 210. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 212. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 214. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 215. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 216. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 217. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 219. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 220. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 221. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 222. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 223. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 224. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 225. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 226. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 228. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 230. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 232. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 233. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 234. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 235. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 237. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 238. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 239. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 240. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 241. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 242. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 243. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 262. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 263. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 264. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 268. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 269. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 270. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 271. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 273. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 274. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 275. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 277. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 278. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 279. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 320. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 322. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 323. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 324. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 325. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 327. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 328. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 329. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 330. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 331. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 332. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DRUG DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 333. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY AUTO-INJECTORS, 2018-2030 (USD MILLION)
TABLE 334. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 335. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 336. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 338. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DERMATOLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THE

Companies Mentioned

  • Allergan plc by Abbvie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • Asterisk Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • DermBiont, Inc.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma S.A.
  • GlaxoSmithkline plc
  • Johnson & Johnson Services, Inc.
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma Group Ltd
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Roivant Sciences Ltd.
  • Shinom Cosmeceuticals

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dermatology Drugs - Global Strategic Business Report - Product Image

Dermatology Drugs - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Dermatological Therapeutics Market by Drug Class, Application - Global Forecast 2025-2030 - Product Image

Dermatological Therapeutics Market by Drug Class, Application - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Dermatology Market by Product Type, Application, End User, Treatment, Patient Age Group - Global Forecast 2025-2030 - Product Image

Dermatology Market by Product Type, Application, End User, Treatment, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Dermatology Treatment and Care Market (2024 Edition): Analysis By Treatment Type (Skin Disease and Care, Hair Disease and Care), By Route of Administration, By End User, By Region: Market Insights and Forecast (2020-2030) - Product Image

Dermatology Treatment and Care Market (2024 Edition): Analysis By Treatment Type (Skin Disease and Care, Hair Disease and Care), By Route of Administration, By End User, By Region: Market Insights and Forecast (2020-2030)

  • Report
  • 247 Pages
  • Global
From
Dermatology OTC Medications Market Report 2025 - Product Image

Dermatology OTC Medications Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Dermatological Drugs Market

The Dermatological Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat skin conditions. These drugs are used to treat a variety of skin conditions, including acne, eczema, psoriasis, and skin cancer. Dermatological drugs are typically administered topically, although some may be taken orally. The Dermatological Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Merck, and Novartis. These companies are engaged in research and development of new drugs, as well as marketing and distribution of existing products. Additionally, many smaller companies are involved in the production of generic dermatological drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.